Pralatrexate: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Pralatrexate. Educational only — not medical advice.
Labeled uses
Pralatrexate injection is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Source: FDA labeling via NIH DailyMed (set a5daa583…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.